Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.65 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076448 | 1.00 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| Hydrochloric Acid SCHEMBL23524368 | 0.98 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| Methamphetamine SCHEMBL28184718 | 0.90 | SIGMAR1 (0.84) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL765297 | 0.82 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| Pholedrine SCHEMBL119262 | 0.80 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL7316113 | 0.80 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| SCHEMBL11265489 | 0.80 | CYP2D6 (0.68) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL18211455 | 0.80 | CYP1A2 (0.68) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| SCHEMBL21286088 | 0.80 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| SCHEMBL178533 | 0.80 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | claimed |
| US-9435816-B2 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods of their preparation and their use | CHIRON AS (NO) | 2016-09-06 | — | — | US | claimed |
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON A/S (NO) | 2014-08-14 | — | — | US | claimed |
| WO-2013014287-A2 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON AS (NO) | 2013-01-31 | — | — | WO | claimed |
| EP-2551675-A1 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use | Chiron AS (NO) | 2013-01-30 | — | — | EP | claimed |
| EP-3841085-B1 | NBOME TEST | UNIV SYDNEY TECHNOLOGY (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | disclosed |
| EP-4683622-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | Pharmapotheca A, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2014013063-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | CHIRON AS (NO) | 2014-01-23 | — | — | WO | disclosed |
| EP-2687854-A1 | Test kit for the quantitative determination of narcotic drugs | Chiron AS (NO) | 2014-01-22 | — | — | EP | disclosed |
| WO-2013014287-A2 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON AS (NO) | 2013-01-31 | — | — | WO | disclosed |
| EP-2551675-A1 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use | Chiron AS (NO) | 2013-01-30 | — | — | EP | disclosed |
| EP-2431362-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | PNMT, HTR2C, HTR2A | TAAR1 16/4885SLC18A2 9/4885SIGMAR1 66/4885 |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | BDNF, NTRK2, GRIN2A | TAAR1 138/4885SLC18A2 49/4885SIGMAR1 51/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | TAAR1 79/4885SLC18A2 35/4885SIGMAR1 1960/4885 |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | SMS, SRMS, SRM | TAAR1 28/4885SLC18A2 180/4885SIGMAR1 20/4885 |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | TAAR1 1125/4885SLC18A2 732/4885SIGMAR1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.